The impact of cytology screening and HPV vaccination on the burden of cervical cancer

被引:7
|
作者
Tay, Kaijun [2 ]
Tay, Sun K. [1 ]
机构
[1] Singapore Gen Hosp, Dept Obstet & Gynaecol, Singapore 169608, Singapore
[2] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore 117595, Singapore
关键词
Cervarix; cost-effectiveness; Gardasil; HPV infection; universal vaccination; HUMAN-PAPILLOMAVIRUS INFECTION; COST-EFFECTIVENESS; NATURAL-HISTORY; PREVALENCE; SINGAPORE; LESIONS;
D O I
10.1111/j.1743-7563.2011.01396.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: To evaluate the impact of different strategies of human papillomavirus (HPV) vaccination on the burden of cervical cancer in Singapore. Methods: The incidence of cervical cancer was calculated using a Markov model with inputs based on Singapore data for the prevalence of HPV infection, socioeconomic characteristics and screening prevalence. The evaluation was performed for 10 scenarios: no screening, current opportunistic cytology screening, ideal optimal screening, universal adolescent HPV vaccination at 12-years old alone and with catch-up cohorts and combinations of screening and vaccination. Results: (1) The model prediction showed that cervical cancer cases were reduced by 6.5% using opportunistic screening, by 34.3% using optimized screening and by 63.9% with a universal HPV vaccination at 12 years of age. (2) Adding optimized screening, but not opportunistic screening, to a universal adolescent HPV vaccination program caused a moderate further reduction in cervical cancer cases. (3) No difference was discernable in the impact of vaccination introduction between the age groups < 20, 20-24 and 25-29 years old. (4) The time required to halve the incidence of cervical cancer was 42 years for universal vaccination at the age of 12 but could be shortened by including catch-up cohorts of women up to 40-years old. Conclusion: A universal HPV vaccination program introduced between the ages of 12-29 is superior to cytology screening in reducing the burden of cervical cancer. However, in the next four decades of post-vaccination era, optimizing the screening program remains the most important measure for cervical cancer prevention.
引用
收藏
页码:154 / 159
页数:6
相关论文
共 50 条
  • [41] HPV testing for cervical cancer screening appears more cost-effective than Papanicolau cytology in Mexico
    Yvonne N. Flores
    David M. Bishai
    Attila Lőrincz
    Keerti V. Shah
    Eduardo Lazcano-Ponce
    Mauricio Hernández
    Víctor Granados-García
    Ruth Pérez
    Jorge Salmerón
    Cancer Causes & Control, 2011, 22 : 261 - 272
  • [42] HPV testing for cervical cancer screening appears more cost-effective than Papanicolau cytology in Mexico
    Flores, Yvonne N.
    Bishai, David M.
    Lorincz, Attila
    Shah, Keerti V.
    Lazcano-Ponce, Eduardo
    Hernandez, Mauricio
    Granados-Garcia, Victor
    Perez, Ruth
    Salmeron, Jorge
    CANCER CAUSES & CONTROL, 2011, 22 (02) : 261 - 272
  • [43] Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage
    Vorno, Triin
    Lutsar, Katrin
    Uuskula, Anneli
    Padrik, Lee
    Raud, Terje
    Reile, Rainer
    Nahkur, Oliver
    Kiivet, Raul-Allan
    VACCINE, 2017, 35 (46) : 6329 - 6335
  • [44] Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study
    Cox, J. Thomas
    Castle, Phillip E.
    Behrens, Catherine M.
    Sharma, Abha
    Wright, Thomas C., Jr.
    Cuzick, Jack
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2013, 208 (03) : 184.e1 - 184.e11
  • [45] HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives
    Castellsague, Xavier
    Schneider, Achim
    Kaufmann, Andreas M.
    Xavier Bosch, F.
    GYNECOLOGIC ONCOLOGY, 2009, 115 (03) : S15 - S23
  • [46] High-Risk HPV Screening Initiative in Kosovo-A Way to Optimize HPV Vaccination for Cervical Cancer
    Bentz, Jessica L.
    Barney, Rachael E.
    Georgantzoglou, Natalia
    Manxhuka-Kerliu, Suzana
    Ibishi, Vlora Ademi
    Dacaj-Elshani, Brikene
    Bejarano, Suyapa
    Palumbo, Paul E.
    Suresh, Arvind
    LaRochelle, Ethan P. M.
    Keegan, William P.
    Wilson, Teresa L.
    Dokus, Betty J.
    Hershberger, Kenneth C.
    Gallagher, Torrey L.
    Allen, Samantha F.
    Palisoul, Scott M.
    Steinmetz, Heather B.
    Kennedy, Linda S.
    Tsongalis, Gregory J.
    DISEASES, 2024, 12 (08)
  • [47] How to screen for cervical cancer after HPV16/18 vaccination in The Netherlands
    Coupe, Veerle M. H.
    de Melker, H. E.
    Snijders, Peter J. F.
    Meijer, Chris J. L. M.
    Berkhof, Johannes
    VACCINE, 2009, 27 (37) : 5111 - 5119
  • [48] HPV-based screening for cervical cancer among women 55-59 years of age
    Bergengren, Lovisa
    Lillsunde-Larsson, Gabriella
    Helenius, Gisela
    Karlsson, Mats G.
    PLOS ONE, 2019, 14 (06):
  • [49] Predicted Cervical Cancer Prevention: Impact of National HPV Vaccination Program on Young Women in South Korea
    Kwak, Kyeongmin
    Hwang, Seung-sik
    CANCER RESEARCH AND TREATMENT, 2024, 56 (03): : 898 - 908
  • [50] Prevalence of abnormal oral cytology and impact of sexual behavior in women with abnormal cervical cytology
    Temizkan, O.
    Aydogan, B.
    Sanverdi, I.
    Sakiz, D.
    Arici, B.
    Karaca, K.
    Basaran, T.
    Yalcin, P.
    Ayhan, I.
    CLINICAL AND EXPERIMENTAL OBSTETRICS & GYNECOLOGY, 2016, 43 (03): : 388 - 392